Literature DB >> 23173613

Nucleotide oligomerization domain 2 polymorphisms in patients with intestinal failure.

Juan Francisco Guerra1, Michael Zasloff, Denver Lough, Joseph Abdo, Jason Hawksworth, Cal Mastumoto, Raffaele Girlanda, Eddie Island, Kirty Shetty, Stuart Kaufman, Thomas Fishbein.   

Abstract

BACKGROUND: Nucleotide oligomerization domain 2 (NOD2) has been associated with intestinal immunity after the discovery that its polymorphisms are linked to Crohn's disease (CD). Intestinal failure (IF) represents a wider spectrum of diseases where intestinal homeostasis has been disrupted. AIM: To evaluate the prevalence of NOD2 mutations in a population with IF as well as its association with the different conditions causing this problem.
METHODS: One hundred ninety-two consecutive patients with IF and 103 healthy controls were genotyped for the three most common NOD2 polymorphisms. Genotypes were compared between the groups and were related to the entities causing IF.
RESULTS: A high percentage (26%) of patients had at least one of the three most common NOD2 polymorphisms, while only a 4.8% of healthy controls had a mutant genotype. In patients with IF, specific mutations for the 702W, 908R and 1007fs alleles were 11, 5 and 12.5%, respectively, compared with 0.9% (P = 0.0003), 1.9% (P = 0.1) and 1.9% (P = 0.001) in the control group. If we consider patients with any cause of IF other than CD, the percentage is still as high as 18.8%, with specific mutation frequencies of 7.6% (702W; P = 0.01), 5.8% (908R; P = 0.1) and 8.2% (1007fs; P = 0.002). We could not establish an association between a NOD2 mutant genotype with any other specific clinical condition other than CD.
CONCLUSION: Our finding supports the importance of NOD2 in the maintenance of intestinal immune homeostasis and may be important to a variety of intestinal stressors.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23173613     DOI: 10.1111/jgh.12037

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

Review 1.  The parallel paradigm between intestinal transplant inflammation and inflammatory bowel disease.

Authors:  Leonid Belyayev; Katrina Loh; Thomas M Fishbein; Alexander Kroemer
Journal:  Curr Opin Organ Transplant       Date:  2019-04       Impact factor: 2.640

Review 2.  When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.

Authors:  Suneeta Krishnareddy; Arun Swaminath
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 3.  Intestinal Transplant Inflammation: the Third Inflammatory Bowel Disease.

Authors:  Alexander Kroemer; Christopher Cosentino; Jason Kaiser; Cal S Matsumoto; Thomas M Fishbein
Journal:  Curr Gastroenterol Rep       Date:  2016-11

4.  Immunologic Complications and Graft Survival in Crohn's Disease and NOD2 Mutant Non-Crohn's Disease Adult Recipients Following Intestine Transplantation.

Authors:  Leonid Belyayev; Jason Hawksworth; Khalid Khan; Stuart Kaufman; Sukanya Subramanian; Alexander Kroemer; Katrina Loh; Raffaele Girlanda; Thomas M Fishbein; Cal S Matsumoto
Journal:  Transplant Direct       Date:  2020-05-21

5.  Two patients with intestinal failure requiring home parenteral nutrition, a NOD2 mutation and tuberculous lymphadenitis.

Authors:  Holger Schäffler; Matthias Teufel; Sabrina Fleischer; Chih-Jen Hsieh; Julia-Stefanie Frick; Georg Lamprecht
Journal:  BMC Gastroenterol       Date:  2014-03-06       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.